Arrowhead licenses ARO-SNCA to Novartis for $200M upfront, up to $2B milestones

ARROWHEAD PHARMACEUTICALS, INC.

Arrowhead receives $200M upfront; eligible for up to $2B in development, regulatory, sales milestones.
Novartis gets exclusive worldwide license to preclinical ARO-SNCA (siRNA for synucleinopathies like Parkinson's).
Arrowhead will complete preclinical work; Novartis handles clinical development, manufacturing, commercialization.
Arrowhead eligible for tiered royalties up to low double digits on net product sales.
Transaction expected to close H2 2025, subject to HSR antitrust clearance and customary conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.